HOME PRODUCTS & ACCESSORIES PARADIGM™ VEO™ CONTINUOUS GLUCOSE MONITORING*

Continuous Glucose Monitoring (CGM) allows you to see your glucose levels 24 hours a day. When used with the Medtronic MiniLink™ Transmitter and glucose sensor, the Paradigm™ Veo™ System will monitor your glucose levels and update your on-screen readings every five minutes. These regular updates may help you to understand how your glucose is behaving by showing you a more complete picture, rather than only a few readings a day that your fingerstick readings provide.¹
The advantages of CGM over traditional fingersticks and HbA1c testing are well-documented. Research has shown that:

• 60% of glucose lows may not be revealed with fingersticks alone^1,2
• CGM identifies four times as many serious glucose excursions as Self-Monitoring of Blood Glucose (SMBG)³
• CGM can significantly reduce HbA1c levels when compared with fingersticks alone^3,4,5
• CGM has shown to be reliable⁶ in studies enabling you to make therapy adjustments based on sensor glucose data.

Continuous glucose monitoring is made possible with the help of a small glucose sensor that you wear for up to 6 days at a time. Just like an infusion set cannula, the sensor is easily inserted using an automatic device provided with the system. The sensor attaches to a small, lightweight Medtronic MiniLink™ Transmitter that sends glucose sensor data wirelessly to the insulin pump through advanced radio frequency (RF) wireless technology.

The insulin pump displays the glucose data on the screen and plots a trend line of the data so that you can see your glucose levels and how they may be affected by what you are doing.

Alerts on the insulin pump will sound or vibrate to warn you when glucose levels are rapidly changing and you are likely to reach, or have reached your glucose target limits. Having this information may help you to avoid hypo- or hyperglycaemic excursions, remain within your target glucose levels and help to reduce your HbA1c.^7,8,9 Here are some details of some REAL-Time alerts:

• Predictive Alerts*
  You can set predictive alerts 5, 10, 15, 20, 25 or 30 minutes before a high or low glucose limit has been reached, allowing you to take early action


• Rate of Change Alerts*
  You are told when glucose levels are rapidly rising or falling, allowing you to take immediate action


• Trend Arrows Alerts*
  Enjoy increased awareness of potential hypo- or hyperglycaemia thanks to the trend arrows, showing how fast and in which direction your glucose has moved over the past 20 minutes


• Low and High Threshold Alerts*
  Benefit from additional monitoring with alerts whenever you are crossing the high or low glucose limit

To learn more about the new Low Glucose Suspend mechanism, click here.

  To download further information (user guides, fact sheets, etc), please click here.
  To access the Paradigm^TM Veo^TM tutorial, click here

1. Gross TM, Mastrototaro JJ. Efficacy and reliability of the continuous glucose monitoring system. Diabetes Technol Ther. 2000;2(suppl 1):S19-S26.
2. Skyler JS. The economic burden of diabetes and the benefits of improved glycaemic control: the potential role of a continuous glucose monitoring system. Diabetes Technol Ther. 2000;2(suppl 1):S7-S12.
3. Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P. A pilot study of the continuous glucose monitoring system: clinical decisions and glycaemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care. 2001;24(12):2030-2034.
4. Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract. 1999;46(3):183- 190.
5. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics. 2003;111(5 pt 1):933-938.
6. Data on file
7. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes:
meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765-774.
8. Deiss D, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29(12):2730-32.
9. Corriveau EA, et al. Effect of Carelink, an internet-based insulin pump monitoring system, on glycemic control in rural and urban children with type 1 diabetes mellitus. Pediatric Diabetes. 2008;9(Part ii):360-366. * Requires the use of CGM. This data is intended to supplement, not replace, blood glucose information obtained using standard home blood glucose monitoring devices. Fingersticks required when adjusting insulin delivery or calibrating the glucose sensor.